<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994798</url>
  </required_header>
  <id_info>
    <org_study_id>T122E2</org_study_id>
    <nct_id>NCT01994798</nct_id>
  </id_info>
  <brief_title>Rapid Exchange Devices Observational Registry.</brief_title>
  <acronym>RX Registry</acronym>
  <official_title>Prospective, Non-randomized, Multicentre, Observational Registry to Assess Clinically Relevant Benefit of Performing the Whole PTA Procedure Using the Rapid Exchange (RX) Devices.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo Europe N.V.</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is designed to assess the clinically relevant benefits of balloon angioplasty
      and stenting in superficial femoral and popliteal artery, using rapid exchange technology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Safety: composite of all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month</measure>
    <time_frame>From start up to 30 Days post procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Total contrast media volume given during the procedure.</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of the procedure</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluoroscopy time</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radiation dose given</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success defined as a successful access and balloon angioplasty followed by stent placement with achieved recanalization determined by less than 30% residual stenosis by angiography at the baseline procedure.</measure>
    <time_frame>Pre- and post-procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success defined as technically successful procedure without the events considered in safety composite endpoint (all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month.</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total acute complication rate defined as any device- or procedure- related complication up to 1 month post procedure.</measure>
    <time_frame>Up to 30 Days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total acute device related complication rate defined as any device complication up to 1 month post procedure.</measure>
    <time_frame>Up to 30 Days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI) improvement at 30 days.</measure>
    <time_frame>30 Days post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the Rutherford index at 30 days.</measure>
    <time_frame>30Days post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance at 30 days compared with walking distance before procedure.</measure>
    <time_frame>30 Days post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complication as per BARC definitions.</measure>
    <time_frame>Up to 30 days post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Lower-extremity Peripheral Arterial Disease.</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with one lesion located in Superficial Femoral Artery(SFA) or popliteal artery
        planned to be treated as per hospital practice with plain old balloon angioplasty and
        nitinol stent using monorail (rapid exchange) delivery system.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic one or two legs ischemia, requiring treatment of SFA or
             popliteal artery

          -  Rutherford classification 2-5

          -  Single lesion with recoiling/dissection/restenosis after balloon angioplasty or de
             novo lesions with stenosis or occlusion,

          -  Target vessel reference diameter ≥4mm and ≤7mm (by visual estimate)

          -  At least one patent (less than 50% stenosis) tibioperoneal run-off vessel confirmed
             by baseline angiography

          -  Patient is suitable candidate for femoral-popliteal artery bypass surgery

        Exclusion Criteria:

          -  Female of child-bearing potential.

          -  Previous bypass surgery

          -  In stent restenosis as a target lesion

          -  Scheduled staged procedure of multiple lesions within the ipsilateral iliac or
             popliteal arteries within 30 days after index procedure.

          -  Co-existing aneurysmal disease of the abdominal aorta, iliac or popliteal arteries

          -  Acute thrombophlebitis or deep venous thrombosis

          -  Hemodynamic instability

          -  Untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent
             stenosis or occlusion),

          -  Significant gastrointestinal bleeding or any coagulopathy that would contraindicate
             the use of anti-platelet therapy

          -  Known intolerance to study medications, contrast agents or nitinol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Martinez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire (CHU) Liège</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Andrés Navarro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Dr. Josep Trueta de Girona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josua Van den Berg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Regionale di Lugano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dragica Paunovic, Dr.</last_name>
    <email>dragica.paunovic@terumo-europe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenhuis (OLV) Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Beelen, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Roel Beelen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen (GZA) Ziekenhuizen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michiel Van Betsbrugge, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Michiel Van Betsbrugge, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional (CHR) du Val de Sambre</name>
      <address>
        <city>Auvelais-Val de Sambre</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cezar Vazquez, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Cezar Vazquez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Lacquet, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Lacquet, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Martinez, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Martinez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dr. Josep Trueta de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omar Andrés Navarro, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Omar Andrés Navarro, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josua Van den Berg, Prof.Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Josua Van den Berg, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
